Land: Irland
Sprache: Englisch
Quelle: HPRA (Health Products Regulatory Authority)
IMIDACLOPRID
Bayer Limited
QP53AX17
IMIDACLOPRID
100 Milligram
Spot On Solution
POM
Canine
Imidacloprid
Ectoparasiticide
Authorised
2001-02-23
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Advantage 100 Spot-on solution for Dogs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION ACTIVE SUBSTANCE: Imidacloprid 100 mg/pipette (1.0 ml of a 10 % solution) EXCIPIENT(S): Butylhydroxytoluene (E 321) 1.0 mg/pipette For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Spot-on solution. Clear yellow to slightly brownish solution. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES For the prevention and treatment of flea infestations and for the treatment of biting lice_ (Trichodectes canis)_ on dogs of 4 kg up to less than 10 kg body weight. For dogs of less than 4 kg body weight or 10 kg body weight and greater, use the appropriate Advantage for Dogs product (see section 4.9). Fleas on dogs are killed within one day following treatment. One treatment prevents further flea infestation for four weeks. The product can be used as part of a treatment strategy for the control of Flea Allergy Dermatitis (FAD) where this has been previously diagnosed by a veterinary surgeon. 4.3 CONTRAINDICATIONS Do not treat unweaned puppies of less than 8 weeks of age. Do not use in animals that are known to be hypersensitive to the active substance or any of the excipients. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ _D_ _a_ _t_ _e_ _ _ _P_ _r_ _i_ _n_ _t_ _e_ _d_ _ _ _2_ _5_ _/_ _0_ _1_ _/_ _2_ _0_ _1_ _7_ _C_ _R_ _N_ _ _ _7_ _0_ _2_ _5_ _1_ _8_ _5_ _p_ _a Lesen Sie das vollständige Dokument